|Dr. Carl Alan Jason Morton Firth||Chairman & CEO||N/A||N/A||1973|
|Mr. Kiran Asarpota||VP of Fin.||N/A||N/A||1979|
|Mr. Ben Goodger||Gen. Counsel||N/A||N/A||1963|
|Dr. Mark McHale Ph.D.||Chief Devel. Officer and Head of R&D||N/A||N/A||1965|
|Charlie Hsu||Investor Relations Director||N/A||N/A||N/A|
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4, as well as gastric cancer. Its Varlitinib is currently being studied in a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, it develops ASLAN005, an antibody that is in preclinical development targeting recepteur d'origine nantais, an immune checkpoint inhibitor. The company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Array BioPharma, Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., Exploit Technologies Pte Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.